Published in Gene Therapy Weekly, April 3rd, 2003
"We have characterized the effect of recombinant insulin-like growth factor (IGF) proteins, as well as third-generation adenoviral vectors encoding either IGF-I or IGF-II genes, on cardiomyocyte apoptosis and on angiogenesis," announced E.J. Su, an investigator at Genetic Therapy, Inc., in Gaithersburg, Maryland.
Su's team, collaborating with colleagues from Novartis, studied IGF-I and -II gene transfer in cultured cells and in an in vivo Matrigel model.
"We found that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-04-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.